Researcher profile

Andrew D. McNaughton

Andrew D. McNaughton contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 13 - UnverifiedVerification L1Unclaimed author
2works
0followers
2topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2024arXiv

Scaffold-Based Multi-Objective Drug Candidate Optimization

In therapeutic design, balancing various physiochemical properties is crucial for molecule development, similar to how Multiparameter Optimization (MPO) evaluates multiple variables to meet a primary goal. While many molecular features can now be predicted using \textit{in silico} methods, aiding early drug development, the vast data generated from high throughput virtual screening challenges the practicality of traditional MPO approaches. Addressing this, we introduce a scaffold focused graph-based Markov chain Monte Carlo framework (ScaMARS) built to generate molecules with optimal properties. This innovative framework is capable of self-training and handling a wider array of properties, sampling different chemical spaces according to the starting scaffold. The benchmark analysis on several properties shows that ScaMARS has a diversity score of 84.6\% and has a much higher success rate of 99.5\% compared to conditional models. The integration of new features into MPO significantly enhances its adaptability and effectiveness in therapeutic design, facilitating the discovery of candidates that efficiently optimize multiple properties.

preprint2022arXiv

De novo design of protein target specific scaffold-based Inhibitors via Reinforcement Learning

Efficient design and discovery of target-driven molecules is a critical step in facilitating lead optimization in drug discovery. Current approaches to develop molecules for a target protein are intuition-driven, hampered by slow iterative design-test cycles due to computational challenges in utilizing 3D structural data, and ultimately limited by the expertise of the chemist - leading to bottlenecks in molecular design. In this contribution, we propose a novel framework, called 3D-MolGNN$_{RL}$, coupling reinforcement learning (RL) to a deep generative model based on 3D-Scaffold to generate target candidates specific to a protein building up atom by atom from the starting core scaffold. 3D-MolGNN$_{RL}$ provides an efficient way to optimize key features by multi-objective reward function within a protein pocket using parallel graph neural network models. The agent learns to build molecules in 3D space while optimizing the activity, binding affinity, potency, and synthetic accessibility of the candidates generated for infectious disease protein targets. Our approach can serve as an interpretable artificial intelligence (AI) tool for lead optimization with optimized activity, potency, and biophysical properties.